Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study

Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(1)

Published: Jan. 2, 2023

Real-world evidence on the effectiveness of COVID-19 vaccines marketed in China against Omicron BA.2.2 variant remains scarce. A case–control study was conducted to estimate vaccine (VE) (inactivated vaccines, an Ad5-nCoV vaccine, and a recombinant protein vaccine). There were 414 cases infected with SARS-CoV-2 828 close contacts whose test results consecutively negative as controls during outbreak Lu'an City, Anhui Province, China, April 2022. The overall adjusted VE infection vaccinated group any 35.0% (95% CI: −9.1–61.3%), whereas for booster vaccination 51.6% 15.2–72.4%). Subgroup analysis showed that (65.8%, 95% 12.8–86.6%) while dose inactivated offered no protection. three-dose 48.0% 8.0–70.6%), two-dose 62.9% 1.8–86%). is protection from vaccine. 46.8% 9.5–68.7%) within six months. statistically significant differences between VEs heterologous (VE = 76.4%, 14.3–93.5%) homologous 51.8%, 9.6–74.3%) (P .036). Booster more than full vaccination. campaign after three doses must be urgently conducted.

Language: Английский

---

Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan

Vaccines, Journal Year: 2023, Volume and Issue: 11(5), P. 920 - 920

Published: April 29, 2023

Booster vaccination reduces the incidence of severe cases and mortality related to COVID-19, with cellular immunity playing an important role. However, little is known about proportion population that has achieved after booster vaccination. Thus, we conducted a Fukushima cohort database assessed humoral in 2526 residents healthcare workers Prefecture Japan through continuous blood collection every 3 months from September 2021. We identified people induced using T-SPOT.COVID test, analyzed their background characteristics. Among 1089 participants, 64.3% (700/1089) had reactive Multivariable analysis revealed following independent predictors immunity: age < 40 years (adjusted odds ratio: 1.81; 95% confidence interval: 1.19–2.75; p-value: 0.005) adverse reactions (1.92, 1.19–3.09, 0.007). Notably, despite IgG(S) neutralizing antibody titers ≥500 AU/mL, 33.9% (349/1031) 33.5% (341/1017) respectively, did not have immunity. In summary, this first study evaluate at level albeit several limitations. Future studies will need previously infected subjects T-cell subsets.

Language: Английский

---

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant

Vaccines, Journal Year: 2022, Volume and Issue: 10(7), P. 986 - 986

Published: June 21, 2022

(1) Background: SARS-CoV-2 infections are associated with an increased risk of hospital admissions especially in the elderly (age ≥ 65 years) and people multiple comorbid conditions. (2) Methods: We investigated effect additional booster vaccinations following primary vaccination series mRNA, inactivated whole virus, or vector vaccines on delta variant total Hungarian population. The infection, admission, 28-day all-cause mortality population was assessed. (3) Results: A 1,984,176 fulfilled criteria including 299,216 unvaccinated individuals, while 1,037,069 had completed 587,150 obtained booster. reduced infection by 48.88%, admission 71.55%, 79.87%. benefit, as were even lower (82.95%; 92.71%; 94.24%, respectively). Vaccinated patients needing hospitalization suffered significantly more conditions, indicating a vulnerable (4) Conclusions: Our data confirmed that delta-variant-associated despite severe

Language: Английский

---

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 2, 2023

Introduction In Hungary, the HUN-VE 3 study determined comparative effectiveness of various primary and booster vaccination strategies during Delta COVID-19 wave. That included more than 8 million 18-100-year-old individuals from beginning pandemic. Immunocompromised (IC) have increased risk for disease course might be severe in them. this study, we wished to estimate SARS-CoV-2 infection related death IC compared healthy ones BNT162b2 vaccine by reassessing data. Patients methods Among 8,087,988 undergoing follow-up onset pandemic cohort, selected all 263,116 patients with a diagnosis corresponding 6,128,518 controls second wave, before vaccinations started. The state was defined as two occurrences ICD-10 codes outpatient or inpatient claims data since 1 January, 2013. control group without chronic diseases. about vaccination, were obtained National Public Health Center (NPHC) Cases reported on daily basis using centralized system via (NPHC). Results Out 12,055 (4.58%) out 202,163 (3.30%) acquired infection. Altogether 436 2141 died relation COVID-19. crude incidence rate ratio (IRR) 1.40 (95%CI: 1.37-1.42) comparing controls. mortality 4.75 4.28-5.27). With respect infection, interestingly, effective Primary (VE) higher restored VE after waning. regarding less individuals. Booster against COVID-19-related both Conclusion There is patient. Moreover, restore impaired these

Language: Английский

---

Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method

Vaccines, Journal Year: 2022, Volume and Issue: 10(11), P. 1824 - 1824

Published: Oct. 29, 2022

Several studies have reported the waning effectiveness of COVID-19 vaccines. This study aims to demonstrate applicability screening method for estimating vaccine (VE) in a pandemic. We report VE Hungary, estimated with method, 2021, covering period Alpha and Delta variant, including booster dose roll-out. Hungary is unique position use six different vaccines same population. All provided high level protection initially, which declined over time. While picture each age group, immunity apparent all vaccines, especially younger groups Sinopharm, Sputnik-V, AstraZeneca performed similarly. clearly reversed by doses, more prominent those three where decline evident. Overall, two Pfizer/BioNTech Moderna, tend produce best results groups, even considered. Using future pandemic waves worthwhile, countries struggling lack resources or when there need deliver within short timeframe due urgent decision-making.

Language: Английский

---

Trends in Intention to Take the Second Booster COVID-19 Vaccination and Associated Factors in China: Serial Cross-Sectional Surveys

Vaccines, Journal Year: 2024, Volume and Issue: 12(5), P. 502 - 502

Published: May 7, 2024

The escalating complexity of the COVID-19 epidemic underscores need for heightened attention to booster vaccinations. This study aims examine changing trend in public's intention receive second vaccination over time and associated factors following policy optimization China.

Language: Английский

---

Omicron neutralization character in patients with breast cancer and liver cancer after the nationwide omicron outbreak

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(11)

Published: June 1, 2024

Abstract Background The surge in omicron variants has caused nationwide breakthrough infections mainland China since the December 2022. In this study, we report neutralization profiles of serum samples from patients with breast cancer and liver who had contracted subvariant infections. Methods real‐world enrolled 143 COVID‐19‐vaccinated (81 62 cancers) 105 unvaccinated (58 47 after infection. Anti‐spike receptor binding domain (RBD) IgGs 50% pseudovirus titer (pVNT 50 ) for preceding (wild type), circulating (BA.4‐BA.5, BF.7), new subvariants (XBB.1.5) were comprehensively analyzed. Results Patients receiving booster doses higher levels anti‐spike RBD IgG against BF.7) a novel compared to Additionally, all vaccinated produced neutralizing antibody titers patients. However, XBB.1.5 than Omicron infection, trend being more pronounced Moreover, found that there was no correlation between wildtype virus titer, but positive Conclusion Our study may be differences vaccine response protective effect COVID‐19 infection cancer. Therefore, recommend strategies should optimized based on components immunology different

Language: Английский

---

Estimation of COVID-19 vaccine effectiveness against infections and severe outcomes using routine surveillance data in Kosovo, July—September 2021

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(7), P. e0305629 - e0305629

Published: July 24, 2024

COVID-19 vaccines have proven effective against severe outcomes in many settings, yet vaccine effectiveness (VE) estimates remain lacking for Kosovo. We aimed to estimate VE infections, hospitalisations, and deaths one two doses during the fourth pandemic wave July-September 2021, period when vaccination initially became widely available.

Language: Английский

---

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine

Diagnostics, Journal Year: 2023, Volume and Issue: 13(3), P. 556 - 556

Published: Feb. 2, 2023

Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine comparison to immunized participants three vaccination. Methods: Sixty-one Caucasian volunteers (39 females, 22 males) vaccinated by included (mean age: 63.9 years). patients (41 20 as controls BNT162b2 59.9 Both groups received the third vaccine. Total anti-SARS-CoV−2 S1-RBD Ig measured an immunoassay (Roche Diagnostics) their calculated ratios after/before dose compared between groups. Results: At baseline, significantly lower antibody determined initial immunization inactivated BNT62b2 (p < 0.001). After boosters, similarly high detected both heterologous (27,195 [15,604–42,754] BAU/mL, p 0.001) homologous cohort (24,492 [13,779−42,671] baseline. Hence, ratio was higher vs Conclusion: To address concept that basic is not effective BNT162b, we effect BNT162b2. Our results suggest can successfully boost effects two-dose

Language: Английский

---

Fatal cases after Omicron BA.1 and BA.2 infection: Results of an autopsy study

International Journal of Infectious Diseases, Journal Year: 2022, Volume and Issue: 128, P. 51 - 57

Published: Dec. 27, 2022

Omicron lineages BA.1/2 are considered to cause mild clinical courses. Nevertheless, fatal cases after those infections recognized but little is known about risk factors.A total of 23 full and three partial autopsies in deceased with have been consecutively performed. The investigations included histology, blood analyses, molecular virus detection.COVID-19-associated diffuse alveolar damage was found only eight (31%). This rate significantly lower compared previous studies, including non-Omicron variants, where rates between 69% 92% were observed. Neither vaccination nor factors associated a direct death by COVID-19. Only patients who admitted the clinic because COVID-19 not for other reasons had significant association -caused (P >0.001).Diffuse still occurred BA.1/BA.2 era at considerably frequency than seen variants concern. None discriminated COVID-19-caused from that died different disease. Therefore, host's genomics might play key role this regard. Further studies should elucidate existence such genomic factor.

Language: Английский

---